BR112016027845A2 - proteínas de fusão de ox40l e usos das mesmas - Google Patents
proteínas de fusão de ox40l e usos das mesmasInfo
- Publication number
- BR112016027845A2 BR112016027845A2 BR112016027845A BR112016027845A BR112016027845A2 BR 112016027845 A2 BR112016027845 A2 BR 112016027845A2 BR 112016027845 A BR112016027845 A BR 112016027845A BR 112016027845 A BR112016027845 A BR 112016027845A BR 112016027845 A2 BR112016027845 A2 BR 112016027845A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion polypeptide
- fusion proteins
- polypeptide subunits
- domain
- methods
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000005829 trimerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a divulgação proporciona subunidades polipeptídicas de fusão de ox40l huigg4 compreendendo o domínio fc da igg4 humana, um domínio de trimerização, e o domínio de ligação do receptor do ligante do ox40, onde as subunidades polipeptídicas de fusão podem se montar em proteínas hexaméricas. também são proporcionados métodos para efetuar subunidades polipeptídicas de fusão e proteínas hexaméricas, e métodos de uso, por exemplo, tratamento de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462004555P | 2014-05-29 | 2014-05-29 | |
US201562111796P | 2015-02-04 | 2015-02-04 | |
PCT/US2015/032598 WO2015183902A1 (en) | 2014-05-29 | 2015-05-27 | Ox40l fusion proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016027845A2 true BR112016027845A2 (pt) | 2017-10-31 |
Family
ID=53540957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016027845A BR112016027845A2 (pt) | 2014-05-29 | 2015-05-27 | proteínas de fusão de ox40l e usos das mesmas |
Country Status (10)
Country | Link |
---|---|
US (1) | US9718870B2 (pt) |
EP (1) | EP3148573A4 (pt) |
JP (1) | JP6666267B2 (pt) |
CN (1) | CN106456734A (pt) |
BR (1) | BR112016027845A2 (pt) |
GB (1) | GB2532817A (pt) |
MX (1) | MX360295B (pt) |
RU (1) | RU2016150096A (pt) |
TW (1) | TW201623327A (pt) |
WO (1) | WO2015183902A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9718870B2 (en) * | 2014-05-29 | 2017-08-01 | Medimmune, Llc | OX40L fusion proteins and uses thereof |
HUE054122T2 (hu) | 2014-11-14 | 2021-08-30 | Hoffmann La Roche | TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák |
CN107208099B (zh) | 2015-02-06 | 2022-05-13 | 热生物制品有限公司 | 共表达疫苗和共刺激分子的载体 |
CN107207579B (zh) | 2015-03-31 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
US11536716B2 (en) * | 2015-06-25 | 2022-12-27 | Hoffmann-La Roche Inc. | Cell based assay for determining antibody or ligand binding and function |
KR20180033588A (ko) | 2015-08-12 | 2018-04-03 | 메디뮨 리미티드 | Gitrl 융합 단백질 및 그의 용도 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN116063566A (zh) | 2015-10-01 | 2023-05-05 | 热生物制品有限公司 | 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法 |
EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
US10331233B2 (en) * | 2016-10-27 | 2019-06-25 | Fluidity Technologies, Inc. | Camera and sensor controls for remotely operated vehicles and virtual environments |
US10331232B2 (en) * | 2016-10-27 | 2019-06-25 | Fluidity Technologies, Inc. | Controller with situational awareness display |
MX2019006624A (es) * | 2016-12-09 | 2019-08-01 | Seattle Genetics Inc | Anticuerpos bivalentes enmascarados por helices superenrolladas. |
CA3047059A1 (en) * | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
US11192933B2 (en) | 2017-02-27 | 2021-12-07 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
US11267856B2 (en) | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
EP3628070B1 (en) * | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
CN109839509A (zh) * | 2019-02-15 | 2019-06-04 | 浠思(上海)生物技术有限公司 | 利用ox40/ox40l的htrf结合分析实验技术筛选潜在激动剂的方法 |
WO2021228836A1 (en) * | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with ox40 activating properties |
EP4277639A2 (en) * | 2021-01-15 | 2023-11-22 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Hybrid and truncated immune cell proteins |
WO2023088437A1 (zh) * | 2021-11-19 | 2023-05-25 | 南开大学 | 重组武装溶瘤病毒组合物及其在til过继治疗中的用途 |
CN114966061B (zh) * | 2022-07-28 | 2022-10-21 | 中国食品药品检定研究院 | 一种抗ox40抗体的生物活性检测方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
US7056695B2 (en) * | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
MXPA03008031A (es) * | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida. |
WO2003076567A2 (en) * | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
EP1810979B1 (en) * | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
AU2013263717B2 (en) * | 2005-05-06 | 2016-05-19 | Providence Health & Services - Oregon | Trimeric OX40L-immunoglobulin fusion protein and methods of use |
EP2650020B1 (en) * | 2005-05-06 | 2016-08-24 | Providence Health & Services - Oregon | Trimeric OX40-immunoglobulin fusion protein and methods of use |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
JP2009518427A (ja) * | 2005-12-08 | 2009-05-07 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | Invivo細胞表面操作 |
CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法 |
US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
US8637637B2 (en) * | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
AU2012371610A1 (en) * | 2012-03-02 | 2014-10-02 | Providence Health & Services - Oregon | Dual OX40 agonist/IL-2 cancer therapy methods |
US9718870B2 (en) * | 2014-05-29 | 2017-08-01 | Medimmune, Llc | OX40L fusion proteins and uses thereof |
US20190194654A1 (en) * | 2014-10-24 | 2019-06-27 | Astrazeneca Ab | Combination |
-
2015
- 2015-05-27 US US14/722,679 patent/US9718870B2/en active Active
- 2015-05-27 RU RU2016150096A patent/RU2016150096A/ru not_active Application Discontinuation
- 2015-05-27 CN CN201580028116.9A patent/CN106456734A/zh active Pending
- 2015-05-27 BR BR112016027845A patent/BR112016027845A2/pt not_active Application Discontinuation
- 2015-05-27 EP EP15799339.5A patent/EP3148573A4/en not_active Withdrawn
- 2015-05-27 WO PCT/US2015/032598 patent/WO2015183902A1/en active Application Filing
- 2015-05-27 GB GB1509062.4A patent/GB2532817A/en not_active Withdrawn
- 2015-05-27 JP JP2016569060A patent/JP6666267B2/ja not_active Expired - Fee Related
- 2015-05-27 MX MX2016014647A patent/MX360295B/es active IP Right Grant
- 2015-05-29 TW TW104117533A patent/TW201623327A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3148573A1 (en) | 2017-04-05 |
RU2016150096A3 (pt) | 2019-01-24 |
JP6666267B2 (ja) | 2020-03-13 |
US9718870B2 (en) | 2017-08-01 |
JP2017519494A (ja) | 2017-07-20 |
MX2016014647A (es) | 2017-05-30 |
CN106456734A (zh) | 2017-02-22 |
GB2532817A (en) | 2016-06-01 |
RU2016150096A (ru) | 2018-07-02 |
US20160024176A1 (en) | 2016-01-28 |
TW201623327A (zh) | 2016-07-01 |
WO2015183902A1 (en) | 2015-12-03 |
EP3148573A4 (en) | 2017-11-15 |
GB201509062D0 (en) | 2015-07-08 |
MX360295B (es) | 2018-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016027845A2 (pt) | proteínas de fusão de ox40l e usos das mesmas | |
BR112018002039A2 (pt) | proteínas de fusão gitrl e usos das mesmas | |
BR112017016705A2 (pt) | agentes de ligação a tnfrsf e uso dos mesmos | |
BR112017025529A2 (pt) | agentes de ligação ao tigit e usos destes | |
EP3733716A4 (en) | DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE | |
BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
CL2019000261A1 (es) | Polipéptidos modificados y usos de los mismos. | |
BR112019010943A2 (pt) | métodos para o tratamento do câncer compreendendo agentes de ligação a tigit | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
BR112018071307A2 (pt) | anticorpos agonistas que ligam cd40 humana e usos dos mesmos | |
SV2017005548A (es) | Proteinas de fusion | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
EA202190903A2 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний | |
DK3468568T3 (da) | Ekstracellulære vesikler der er afledt af humantrombo-cytlysat, til anvendelse i medicin | |
EP3390443A4 (en) | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANTS OF FC REGIONS, AND METHODS OF USE | |
DK4095130T3 (da) | Mærkede hæmmere af prostataspecifikt membranantigen (psma), deres anvendelse som billeddannelsesmidler og farmaceutiske midler til behandling af prostatacancer | |
GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
DK3655006T3 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse deraf | |
BR112015013127A2 (pt) | imunoterapia com agentes de ligação | |
BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
MY191944A (en) | Binding proteins and methods of use thereof | |
BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
WO2014145016A3 (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |